Insights

This discussion outlines a panel discussion on advances in advanced/recurrent endometrial cancer, emphasizing how long-term trial outcomes and real-world evidence are reshaping treatment selection, sequencing, toxicity management, and future priorities across molecular subgroups.

In this OncLive® Insights: My Treatment Approach program, Amitkumar Mehta, MD, and nurse practitioner Lucy Bailey discuss the rapidly evolving treatment landscape for relapsed/refractory follicular lymphoma. With the emergence of bispecific antibodies, CD19-directed therapies, and CAR T-cell therapy, clinicians now have an unprecedented range of options beyond traditional regimens such as rituximab + lenalidomide (R2) or bendamustine-based chemoimmunotherapy. The faculty review how to evaluate patients after relapse, balance efficacy with toxicity, and select optimal therapies based on disease biology, comorbidities, social factors, and practice setting. They highlight the importance of monitoring for transformation, the nuances of lenalidomide dosing, and the expanding role of community practices in administering novel agents. Through case-based discussions, they outline practical strategies to enhance safety, minimize hospitalization, and foster partnerships between academic centers and community clinicians. The program provides clear, actionable guidance for optimizing outcomes in patients with relapsed follicular lymphoma.

Experts discuss complex hypothetical patient case scenarios in non–small cell lung cancer (NSCLC), highlighting current screening and testing methodologies, diagnostic challenges, and best practices in management.

• Discuss evolving treatment landscape of HER2-directed therapies in NSCLC
• Evaluate sequencing strategies for HER2-targeted ADCs and TKIs
• Interpret the role of HER2 mutation and overexpression testing in clinical practice

This series highlights an international exchange between a US oncologist and a German oncologist on screening and testing practices for non-small cell lung cancer (NSCLC). Experts discuss the current landscape of testing panels and share practical pearls on improving efficiencies in daily practice.

Panelists discuss how evolving molecular classification, improved detection methods, and emerging data from novel tyrosine kinase inhibitors like firmonertinib are transforming the treatment of non–small cell lung cancer (NSCLC) with EGFR PACC mutations. They highlight a future where advanced sequencing and innovative therapeutic strategies will enable more precise, effective, and durable management of this complex molecular subset.

Panelists discuss the role of biomarker testing, when it should be performed, and how comprehensive profiling can shape individualized care. Panelists discuss the evolving treatment landscape for FGFR2b-positive gastric cancer, highlighting key ongoing and late-phase trials as well as future approvals on the horizon. Panelists discuss how biomarker-driven decision-making guides therapy selection, considering how molecular findings, clinical characteristics, and emerging data influence both first-line and subsequent treatment strategies.

Panelists discuss evolving first- and second-line treatment strategies for extensive-stage small cell lung cancer, emphasizing evidence-based integration of immunotherapy, personalized maintenance approaches, toxicity management, and the promise of emerging targeted and immune-based therapies to improve survival and quality of life.

Panelists discuss the rapidly evolving frontline management of advanced renal cell carcinoma, highlighting progress in combination immunotherapy, precision-based treatment, toxicity management, and the promise of emerging therapies that are reshaping the standard of care.

Panelists discuss how innovative treatment strategies, including immune-based and cell-directed therapies, are transforming care for patients with relapsed or refractory follicular and marginal zone lymphomas by improving long-term outcomes, enhancing safety, and prioritizing patient-centered approaches that balance efficacy, quality of life, and access to advanced, personalized treatment options.

Panelists discuss how patients with unresectable hepatocellular carcinoma present with dual challenges of managing both the cancer and underlying cirrhotic liver disease, emphasizing the complexity of applying clinical trial data from patients with Child-Pugh A status to the more heterogeneous Child-Pugh B population commonly seen in practice.

Panelists discuss how intravenous administration of immune checkpoint inhibitors creates operational challenges, including infusion chair bottlenecks, complex scheduling, venous access difficulties, and time burdens for patients, while subcutaneous formulations offer potential solutions through simplified delivery, reduced infusion center strain, and improved patient convenience.

Panelists discuss how recent FDA-approved therapies for chronic graft-vs-host disease (GVHD; ibrutinib, ruxolitinib, belumosudil, and axatilimab) have transformed treatment approaches by enabling earlier intervention after steroid failure, targeting distinct immunological pathways, and improving patient outcomes through personalized treatment sequencing based on organ involvement, toxicity profiles, and practical considerations like oral vs intravenous administration.

Panelists discuss how CAR T-cell therapy has evolved from a highly toxic inpatient treatment to a safer, increasingly accessible therapy that can often be administered on an outpatient basis, with improved patient outcomes when referred early in the treatment journey and enhanced collaboration between academic centers and community oncologists for optimal patient care.

Komal Jhaveri, MD, FACP; and Kevin M. Kalinsky, MD, MS, discuss how emerging oral selective estrogen receptor degraders and proteolysis-targeting chimeras are transforming breast cancer treatment by providing new targeted options for ESR1-mutant tumors, the evolving role of CDK4/6 inhibitor sequencing strategies including molecular progression–based treatment switching, and the integration of antibody-drug conjugates across different breast cancer subtypes from later-line to first-line metastatic settings.

Panelists discuss how HER2 mutations in metastatic non–small cell lung cancer (mNSCLC) require comprehensive molecular testing including both next-generation sequencing and immunohistochemistry, and how the recent FDA approval of zongertinib as a HER2-specific tyrosine kinase inhibitor provides a new targeted therapy option with superior tolerability compared with trastuzumab deruxtecan, emphasizing the importance of proper treatment sequencing and the evolving landscape from chemotherapy-based approaches to precision medicine in this patient population.

Panelists explore treatment strategies and the integral role of the multidisciplinary care team in optimizing outcomes in CML.

Experts discuss the evolving treatment landscape of pediatric low-grade glioma (pLGG), including molecular testing, frontline and relapsed therapy strategies, multidisciplinary decision-making, and real-world case applications to optimize personalized care.